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Abstract
Background: In sub-Saharan Africa the recommended strategy to control schistosomiasis is preventive chemotherapy.
Emphasis is placed on school-aged children, but in high endemicity areas, preschool-aged children are also at risk, and
hence might need treatment with praziquantel. Since a pediatric formulation (e.g., syrup) is not available outside of Egypt,
crushed praziquantel tablets are used, but the efficacy and safety of this treatment regimen is insufficiently studied.
Methodology: We assessed the efficacy and safety of crushed praziquantel tablets among preschool-aged children (,6
years) in the Azaguie´ district, south Coˆte d’Ivoire, where Schistosoma mansoni and S. haematobium coexist. Using a cross-
sectional design, children provided two stool and two urine samples before and 3 weeks after treatment. Crushed
praziquantel tablets, mixed with water, were administered at a dose of 40 mg/kg. Adverse events were assessed and graded
4 and 24 hours posttreatment by interviewing mothers/guardians.
Principal Findings: Overall, 160 preschool-aged children had at least one stool and one urine sample examined with
duplicate Kato-Katz thick smears and a point-of-care circulating cathodic antigen (POC-CCA) cassette for S. mansoni, and
urine filtration for S. haematobium diagnosis before and 3 weeks after praziquantel administration. According to the Kato-
Katz and urine filtration results, we found high efficacy against S. mansoni (cure rate (CR), 88.6%; egg reduction rate (ERR),
96.7%) and S. haematobium (CR, 88.9%; ERR, 98.0%). POC-CCA revealed considerably lower efficacy against S. mansoni (CR,
53.8%). Treatment was generally well tolerated, but moderately severe adverse events (i.e., body and face inflammation),
were observed in four Schistosoma egg-negative children.
Conclusions/Significance: Crushed praziquantel administered to preschool-aged children at a dose of 40 mg/kg is
efficacious against S. mansoni and S. haematobium in a co-endemic setting of Coˆte d’Ivoire. Further research is required with
highly sensitive diagnostic tools and safety must be investigated in more depth.
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Introduction
Schistosomiasis is still a major public health problem in many
parts of the developing world, especially in sub-Saharan Africa [1–
5]. Indeed, more than 200 million people are infected, with about
half of them suffering from morbid sequelae, including hematuria,
dysuria, nutritional deficiencies, anemia, and delayed physical and
cognitive development [1,5–9]. The anthelmintic drug praziquan-
tel is the cornerstone for morbidity control with millions of people
treated every year [10–14]. Morbidity control is emphasized since
the mid-1980s, and this strategy has been reinforced in 2001 by
the World Health Assembly (WHA) resolution 54.19, which urged
member states to regularly de-worm at least 75% and up to 100%
of school-aged children at risk of schistosomiasis and soil-
transmitted helminthiasis [10,15].
Preschool-aged children (individuals below the age of 5–6 years)
are currently excluded from preventive chemotherapy control
campaigns. The main reasons for this exclusion are that preschool-
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aged children are believed to be at low risk of schistosomiasis [16],
and that there is insufficient data documenting the safety and
efficacy of praziquantel in this age group [17,18]. However, recent
studies carried out in different parts of East and West Africa
showed that in high endemicity areas a considerable proportion of
preschool-aged children are already infected with Schistosoma, and
hence treatment might need to be extended to younger age groups
in such high-risk areas [19–29].
With regard to morbidity control of schistosomiasis using
praziquantel, it is important to note that an appropriate pediatric
formulation for treating preschool-aged children is currently not
available outside of Egypt (i.e., praziquantel syrup, Epiquantel,
manufactured by the Egyptian International Pharmaceutical
Industries Co. A.R.E., Cairo, Egypt). Hence, a common approach
in high endemicity areas is to use praziquantel tablets (600 mg),
crush them between two spoons, mix with water or fruit juice, and
then administer orally to preschool-aged children at a dose of
40 mg/kg [17,23,24]. Recent studies using Epiquantel in pre-
school-aged children revealed similar efficacy than crushed
praziquantel tablets [28,30].
The study reported here was designed to assess the efficacy and
safety of crushed praziquantel tablets in preschool-aged children
(,6 years) in an area where Schistosoma mansoni and S. haematobium
coexist [31,32]. Our findings, along with other investigations
pertaining to the epidemiology of schistosomiasis in preschool-
aged children, may be useful to further optimize the control of
schistosomiasis in a currently neglected age group.
Methods
Ethics Statement
Ethical approval was granted by the Ministry of Health and
Public Hygiene of Coˆte d’Ivoire (reference no. 4248/2010/
MSHP/CNER). The trial is registered with ClinicalTrial.gov
(identifier: ISRCTN 53172722) and the protocol is available as
Supporting Information (Protocol S1). Local authorities of the
Azaguie´ district were informed about the purpose, procedures, and
potential risks and benefits of the study. In the absence of recent
census data, an exhaustive door-to-door survey was carried out to
identify all preschool-aged children (,6 years) in the two selected
villages. Parents or guardians of eligible children were informed
about the objectives of the study and asked to provide written
informed consent on behalf of their children. Only those
preschool-aged children who had written informed consent from
their parents/guardians were included.
Participation was voluntary and parents/guardians could
withdraw their child from the study anytime without further
obligation. At the end of the study, anthelmintic drugs (i.e.,
praziquantel against schistosomiasis and albendazole against soil-
transmitted helminthiasis) were offered free of charge to all
community members.
Study Area and Population
The study was conducted between June and November 2011 in
two villages located in the district of Azaguie´, southern Coˆte
d’Ivoire: Azaguie´ Makouguie´ (geographical co-ordinates
05u379330N latitude, 04u099040W longitude) and Azaguie´
M’Brome´ (05u399420N, 04u089380W). Recent studies have shown
that S. mansoni and S. haematobium are co-endemic in Azaguie´ [31–
33]. Villagers are mainly engaged in subsistence farming. Both
villages lack access to clean water and improved sanitation.
Study Design and Sample Size
We pursued an intervention study (i.e., praziquantel adminis-
tration), including children of both sexes below the age of 6 years.
Children’s infection with S. mansoni and S. haematobium was assessed
during a baseline cross-sectional survey and again 3 weeks
posttreatment using standardized, quality-controlled methods.
The STROBE checklist is available as Supporting Information
(Checklist S1).
With the overarching goal to further the understanding of the
epidemiology, diagnosis, and control of schistosomiasis in
preschool-aged children, we aimed at a sample of about 200
individuals, as recommended by statistical textbooks in health
studies [34]. Our population census carried out in June 2011
revealed 367 preschool-age children. We assumed that the
prevalence of S. mansoni in preschool-aged children would be
around 20% (i.e., a quarter of the 80% S. mansoni infection
prevalence observed in school-aged children in Azaguie´ in 2010
[31]) and that about 70% of the preschool-aged children would
comply (lower rate than among school-aged children due to the
difficulty to obtain biological samples in this younger age group).
Aiming for a precision of 5%, we finally decided to include all 367
registered preschool-aged children.
Inclusion Criteria
We adhered to the following inclusion criteria: (i) preschool-
aged children (,6 years); (ii) written informed consent by parents/
guardians; (iii) submission of at least one sufficiently large stool
sample for duplicate Kato-Katz thick smears, and one urine
sample for a 10 ml filtrate and a single point-of-care circulating
cathodic antigen (POC-CCA) cassette test; (iv) no abnormal
medical condition, as judged by the study physician on the day of
the treatment; (v) no recent anthelmintic treatment (within the past
4 weeks) according to a parental questionnaire; and (vi) no
participation in any other clinical trial.
Parasitological and Clinical Examinations
The door-to-door census carried out in June 2011 to establish
up-to-date census data generated lists of preschool-aged children,
including their name, age, sex, and geographical coordinates of the
Author Summary
Schistosomiasis is a parasitic worm infection that plagues
more than 200 million people in the developing world,
particularly in sub-Saharan Africa. The current strategy to
control schistosomiasis is to regularly administer the
deworming drug praziquantel to school-aged children.
Younger children before reaching school-age are not
included in these deworming campaigns, because they are
considered at low risk of schistosomiasis, and because the
amount of available data to evaluate the safety of
praziquantel in young children is insufficient. We conduct-
ed a study in two villages in southern Coˆte d’Ivoire and
examined the stool and urine of more than 250 children
(,6 years) for schistosome eggs and antigens. Children
were treated with crushed praziquantel tablets (40 mg/kg)
and the efficacy of this treatment was determined 3 weeks
after treatment. The safety of the treatment was assessed
by interviewing mothers of treated children for adverse
events (e.g., abdominal pain, diarrhea, and headache).
Complete data records were available for 160 children.
Praziquantel cleared most of the infections. The treatment
was generally well tolerated, but we observed four
children who were not infected at the baseline survey
who developed face and body inflammation that required
close supervision by the study physician.
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household. Mothers/guardians of the preschool-aged children
were provided with plastic containers labeled with unique
identifiers (IDs) and they were asked to obtain a fresh stool and
urine sample of their child. Stool and urine samples were collected
at any time of the day due to the difficulty of collecting biological
samples in this age group. Our aim was to obtain two stool and
two urine samples over two consecutive days from each
participating child.
Laboratory Procedures
Stool and urine samples were transferred to a nearby laboratory
in Azaguie´ town and worked up on the day of collection. For the
diagnosis of S. mansoni and soil-transmitted helminths, duplicate
Kato-Katz thick smears were prepared from each stool sample
(i.e., quadruplicate Kato-Katz thick smears per child), using
41.7 mg templates [35]. The Kato-Katz thick smears were allowed
to clear for at least 30 min before examination under a microscope
by experienced laboratory technicians. The number of S. mansoni
and soil-transmitted helminth eggs were counted and recorded for
each species separately.
For the diagnosis of S. haematobium, urine samples were subjected
to a filtration method, as described elsewhere [36]. Briefly, a single
filtration was performed with each urine sample (i.e., two urine
filtrations per child over two consecutive days). Urine samples
were vigorously shaken and 10 ml pressed through a small-meshed
filter (aperture: 30 mm) and a drop of Lugol’s solution was added
on the filter paper, which was then placed onto a microscope slide.
Slides were examined under a microscope and the number of S.
haematobium eggs counted by experienced technicians.
For quality control, 10% of the Kato-Katz thick smears and the
urine filter slides were re-examined by a senior technician. In case
of disagreement, the results were discussed with the concerned
technician and discordant slides re-read until agreement was
reached.
An additional approach for the diagnosis of S. mansoni was
employed, namely a POC-CCA cassette, that is based on a
commercially available lateral flow immuno-chromatographic test
[31]. The POC-CCA cassette (batch 33112) was performed
according to the manufacturer’s instructions. In brief, a drop of
urine was added to the well and once fully absorbed a drop of
buffer was added. The tests were read within 20–25 min. In case
the control band failed to develop, the test was considered invalid
and the respective urine sample retested with a new POC-CCA.
Valid tests were scored as negative or positive, the latter stratified
into trace (very light color band), 1+, 2+, and 3+ according to the
visibility of the color reaction. The tests were scored independently
by two investigators. In case of conflicting results, a third
investigator was consulted, and the results discussed until
agreement was reached [31].
Praziquantel Treatment and Monitoring of Adverse
Events
Children were treated with crushed praziquantel tablets
(600 mg; Biltricide, Bayer) at a dose of 40 mg/kg [10]. Children
were weighed using an electronic balance (Evolis; Rumily, France).
The appropriate number of praziquantel tablets (e.g., half a tablet
for a child weighing 7–8 kg) were crushed between two spoons,
mixed with tap water in a clean soup spoon before oral
administration. Treatment was given by the mothers/guardians
of the children under close supervision of trained medical
personnel. Children were closely monitored by medical staff for
4 hours. In case vomiting occurred within 1 hour after treatment,
a second dose of praziquantel was administered.
Treatment-related adverse events were assessed 4 and 24 hours
posttreatment. Mothers/guardians were asked to report unusual
behavior of their children since drug intake, and whether any of
the following adverse events occurred: abdominal pain, allergic
reaction, diarrhea, dizziness, fatigue, fever, headache, nausea, and
vomiting. Adverse events were graded (i.e., light, moderate, severe,
or life threatening), as described elsewhere [37].
Treatment Efficacy Evaluation
Three weeks after praziquantel administration, stool and urine
samples were collected again, using the same procedures.
Treatment efficacy was determined by means of cure rate (CR,
percentage of children positive at the pretreatment cross-sectional
survey who became egg-negative 3 weeks after treatment, as
assessed by the Kato-Katz technique for S. mansoni and urine
filtration for S. haematobium) and egg reduction rate (ERR,
reduction in the group’s geometric mean fecal egg count for S.
mansoni or the group’s geometric mean S. haematobium egg count in
10 ml of urine comparing the before and after treatment
situation).
Statistical Analysis
Data were double entered into an Excel spreadsheet,
transferred into EpiInfo version 3.2 (Centers for Disease Control
and Prevention; Atlanta, USA) and cross-checked. Statistical
analyses were done with Stata version 10 (Stata Corp.; College
Station, USA). Preschool-aged children who had at least one
stool sample examined with duplicate Kato-Katz thick smears, a
single POC-CCA cassette for S. mansoni diagnosis, and one urine
sample subjected to a filtration method for S. haematobium
diagnosis before and after treatment were included in the final
analysis (per-protocol). Continuous data (e.g., schistosome egg
counts) are presented as geometric mean, whereas dichotomous
data (e.g., presence or absence of an infection) are presented as
proportion.
Infection intensities were stratified according to cut-offs
proposed by the World Health Organization (WHO) [10].
There are three intensity classes for S. mansoni: (i) light (i.e., 1–99
eggs/gram of stool (EPG)); (ii) moderate (100–399 EPG); and (iii)
heavy ($400 EPG). S. haematobium infections were categorized as
light (1–49 eggs/10 ml of urine) and heavy ($50 eggs/10 ml of
urine).
Results
Adherence and Population Characteristics
Figure 1 shows the adherence of preschool-aged children to the
study protocol. The village census revealed 367 children aged
below 6 years, all of whom were invited to participate. Sixty-three
children were absent during the baseline survey and 16 had no
written informed consent by their parents/guardians. From the
288 children participating at the baseline cross-sectional survey,
seven were excluded due to incomplete parasitological data (e.g.,
insufficiently large stool sample for duplicate Kato-Katz thick
smears). Among the remaining 281 children, 234 were adminis-
tered crushed praziquantel. Three weeks posttreatment, we were
able to re-examine at least one sufficiently large stool and urine
sample from 160 children.
Our final study cohort consisted of 82 (51.3%) boys and 78 girls
with an average age of 3.2 years (range: 5 months to 5 years). Boys
were slightly younger than girls (average, 3.0 years; 95%
confidence interval (CI), 2.7–3.3 years versus average, 3.3 years;
95% CI, 3.0–3.6 years).
Efficacy and Safety of Praziquantel in Preschooler
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Baseline Characteristics
Table 1 shows the pretreatment S. mansoni and S. haematobium
infections, stratified by children’s sex and diagnostic approach.
According to at least duplicate Kato-Katz thick smears, 35
children of our per-protocol population (21.9%) were found S.
mansoni-positive, with a geometric mean infection intensity of 1.2
EPG (Table 2). According to the POC-CCA results, there were
128 S. mansoni infections (80.0%) when considering ‘trace’ results as
positive, and 78 (48.7%) considering ‘trace’ results as negative.
With regard to S. haematobium, the urine filtration method revealed
18 infections (11.2%). The geometric mean infection intensity was
1.0 eggs/10 ml of urine. Eleven children (6.9%) were co-infected
with S. mansoni and S. haematobium.
The Kato-Katz technique also allows detection of soil-
transmitted helminth eggs. The observed prevalence of Trichuris
trichiura, hookworm and Ascaris lumbricoides was 10.9%, 5.9% and
3.8%, respectively.
Praziquantel Efficacy
Table 2 summarizes CR and ERR, stratified by diagnostic
approach. According to the Kato-Katz technique, at the 3-week
posttreatment follow-up, four children (2.5%) were identified with
S. mansoni eggs in their stool with a geometric mean infection
intensity of 0.04 EPG. The CR and ERR was 88.6% and 96.7%,
respectively. The POC-CCA results only allowed estimating CR.
Including or excluding ‘traces’ as positive results, revealed 79 and
Figure 1. Flow chart and study adherence. The study was carried out in the villages of Azaguie´ Makouguie´ and Azaguie´ M’Brome´ in south Coˆte
d’Ivoire, between June and November 2011.
doi:10.1371/journal.pntd.0001917.g001
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36 S. mansoni-infected children, respectively, at the 3-week
posttreatment follow-up. The respective CRs were 38.3% and
53.8%.
With regard to S. haematobium, two children (1.3%) had a positive
urine filtration at the 3-week posttreatment follow-up with a
geometric mean infection intensity of 0.02 eggs/10 ml of urine.
The CR and ERR were 88.9% and 98.0%, respectively.
Figure 2 shows infection intensity categories of S. mansoni and S.
haematobium at the baseline and posttreatment surveys. At baseline,
among 35 S. mansoni-infected children, 23, nine and three children
had light, moderate and heavy infections, respectively. With
regard to S. haematobium, 17 children and one child were lightly or
heavily infected, respectively. At the 3-week posttreatment follow-
up all children who were still Schistosoma-positive had light
infections.
Adverse Events
Table 3 shows the incidence of adverse events 4 and 24 hours
after praziquantel administration among the 234 treated children.
Overall, 43 children reported to have adverse events. Among these
children, 12 (27.9%) were coinfected with S. mansoni and S.
haematobium, 17 (39.5%) had S. mansoni single infection, no child
was infected with S. haematobium only, and 14 children (32.6%)
were not infected at all. We stratified adverse events into two
independent groups. The first group designated children with
adverse events reported within 4 hours posttreatment and the
second group was made up by children with adverse events
reported by their mothers/guardians 24 hours posttreatment.
Most of the adverse events were observed within the first 4 hours
after treatment (n=32, 74.4%), including abdominal pain (n=7),
diarrhea (n=6), nausea (n=5), vomiting (n=4), dizziness (n=3),
fever (n=2), fatigue (n=2), face and body inflammation (n=2),
and headache (n=1). More than one adverse event was observed
in three (abdominal pain and diarrhea), two (vomiting and nausea)
and one (fever and dizziness) children within 4 hours posttreat-
ment. Twenty-four hours posttreatment, 11 (25.6%) children
reported adverse events, including diarrhea (n=3), abdominal
pain (n=2), fatigue (n=2), face and body inflammation (n=2),
dizziness (n=1), and headache (n=1). At this time point, none of
the children reported multiple adverse events.
Table 1. Baseline prevalence of S. mansoni and S. haematobium, stratified by sex and diagnostic approach.
Species Diagnostic approach Sex No. of children examined No. (%) of infected children
S. mansoni Kato-Katz Male 82 19 (23.2)
Female 78 16 (20.5)
Total 160 35 (21.9)
POC-CCA test (incl. trace) Male 82 68 (82.9)
Female 78 60 (76.9)
Total 160 128 (80.0)
POC-CCA test (excl. trace) Male 82 44 (53.7)
Female 78 34 (43.6)
Total 160 78 (48.7)
S. haematobium Urine filtration Male 82 9 (10.9)
Female 78 9 (11.5)
Total 160 18 (11.2)
The study was carried out in two villages in Azaguie´, south Coˆte d’Ivoire, between June and November 2011. All preschool-aged children who had at least one stool
sample examined with duplicate Kato-Katz thick smears and one urine sample subjected to a filtration method before and 3 weeks after praziquantel administration
were included (per-protocol analysis).
POC-CCA, point-of-care circulating cathodic antigen.
doi:10.1371/journal.pntd.0001917.t001
Table 2. S. mansoni and S. haematobium cure and egg reduction rates, as assessed 3 weeks after praziquantel treatment, stratified
by diagnostic approach.
Species
Diagnostic
approach No. (%) of infected children CR in % (95% CI)
Geometric mean infection intensity
(95% CI) ERR in %
Baseline Follow-up Baseline Follow-up
S. mansoni Kato-Katz 35 (21.9) 4 (2.5) 88.6 (73.3–96.8) 1.2 (0.9–1.4) EPG 0.04 (0–0.09) EPG 96.7
POC-CCA test (incl.
trace)
128 (80.0) 79 (49.4) 38.3 (29.8–47.3) NA NA NA
POC-CCA test (excl.
trace)
78 (48.7) 36 (22.5) 53.8 42.2–65.2) NA NA NA
S. haematobium Urine filtration 18 (11.2) 2 (1.3) 88.9 (65.3–98.6) 1.0 (0.9–1.1) eggs/
10 ml urine
0.02 (0–0.06) eggs/
10 ml urine
98.0
The study was carried out in two villages in Azaguie´, south Coˆte d’Ivoire, between June and November 2011, focusing on preschool-aged children.
CI, confidence interval; CR, cure rate; EPG, eggs/gram of stool; ERR, egg reduction rate; NA, not applicable; POC-CCA, point-of-care circulating cathodic antigen.
doi:10.1371/journal.pntd.0001917.t002
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Adverse events were considered of light severity, with the only
exception of face and body inflammation that was graded as a
moderately severe. Mothers/guardians with children experiencing
body and face inflammation sought advice from the study
physician who assured the mothers that this adverse event is
transient and self-limiting. Indeed, within 24 hours, children’s
conditions resolved to normal. The four children complaining of
body and face inflammation were all Schistosoma egg-negative
according to Kato-Katz and urine filtration results, but one had a
positive POC-CCA test results (1+).
Discussion
The anthelmintic drug praziquantel is the cornerstone for
morbidity control due to schistosomiasis [2,10–14]. Emphasis is
placed on school-aged children, whereas preschool-aged children
(individuals below the age of 5–6 years) are usually excluded from
preventive chemotherapy. However, in highly endemic areas, a
considerable amount of preschool-aged children is already affected
by schistosomiasis [19–29]. For that reason, there is ongoing
discussion whether preventive chemotherapy with praziquantel
Figure 2. S. mansoni and S. haematobium infection status of preschool-aged children before and 3 weeks after praziquantel
administration. Parasitological results are based on duplicate Kato-Katz thick smear examinations (for S. mansoni) and urine filtration (for S.
haematobium).
doi:10.1371/journal.pntd.0001917.g002
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should be extended to preschoolers [17,24,25,28–30,38,39].
However, absorption and metabolism of drugs are age-dependent
[18] and it is not well understood whether the developmental
changes in the physiology during biological maturation from
newborns to adolescence influence the efficacy and toxicity of
praziquantel. We assessed the efficacy and safety of crushed
praziquantel among preschool-aged children in an area of south
Coˆte d’Ivoire where S. mansoni and S. haematobium coexist [31,32].
Our study confirms that preschool-aged children are at risk of
schistosomiasis. Indeed, we found that more than 20% of the
children before their sixth birthday were infected with either S.
mansoni or S. haematobium, or both species concurrently (7%). Using a
commercially available POC-CCA cassette test, more than half of the
children showed positive S. mansoni antigen reactions. Our study
reveals that crushed praziquantel (40 mg/kg) administered to
preschool-aged children is highly efficacious with CRs around 90%
and ERRs above 95%, when standard diagnostic methods (Kato-
Katz for S. mansoni and urine filtration for S. haematobium) were used.
There are two limitations of our study worth highlighting. First,
we initially aimed to obtain two stool samples (for quadruplicate
Kato-Katz thick smears) and two urine samples (for duplicate
urine filtration and duplicate POC-CCA cassette test) from each
participant before and after praziquantel administration. Howev-
er, it proved difficult to obtain multiple stool and urine samples in
this age group, and hence we finally included preschool-aged
children who had at least duplicate Kato-Katz thick smears and a
single urine filtration before and after treatment. In view of this
sampling effort and diagnostic approach, it is clear that we have
missed some infections, particularly those of light intensity.
Second, a considerable proportion of preschool-aged children
were lost to follow-up. However, comparing our per-protocol
population (n=160) with children with incomplete parasitological
data, who were absent at treatment, or lost to follow-up (n=121),
we found comparable prevalence estimates and infection intensi-
ties with S. mansoni and S. haematobium.
In spite of the aforementioned limitations, our investigation
provides new insight into the efficacy and safety of praziquantel
among a neglected population group in a S. mansoni-S. haematobium
co-endemic area. Our findings support previous studies conducted
in other parts in Africa. For example, a recent study carried out in
preschool-aged children in Uganda, using quadruplicate Kato-
Katz thick smears (two stool samples, each examined by duplicate
Kato-Katz), reported a slightly lower efficacy against S. mansoni
(CR, 80.2%; ERR, 87.9%) [17]. Mutapi and colleagues in a study
done in Zimbabwe with children aged 1–5 years found high CR
(92%) and very high ERR (99%) of crushed praziquantel against S.
haematobium [40]. Of considerable concern are recent findings from
Ugandan preschool-aged children, as the overall CR among 305
S. mansoni egg-patent individuals was only 56.4%, with particularly
low CR observed in preschoolers with a history of previous
praziquantel treatments (CR 41.7%) [29]. It should also be noted
that the process of crushing praziquantel tablets is time consuming,
and hence poses a challenge for large-scale control programs. It is
encouraging to note that efforts are under way to develop a
pediatric formulation of praziquantel, for example oro-dispersable
tablets or minitablets that might be more convenient to administer
to small children [30].
In our study, we not only used standard diagnostic tests (i.e.,
Kato-Katz and urine filtration) but also a more recently developed
and now commercially available POC-CCA cassette applied to
urine for the diagnosis of S. mansoni (Rapid Medical Diagnostics,
Pretoria, South Africa). Considering POC-CCA results from the
pre- and posttreatment surveys, including or excluding ‘trace’
results as positive, we found low CRs of 38.0% and 53.8%,
respectively. These results are worrying and reasons explaining the
differences in CR according to the diagnostic technique might be
explained as follows. First, S. mansoni eggs might have been missed
by the Kato-Katz technique, particularly at the posttreatment
follow-up when the remaining positive children had very low
infection intensities. Indeed, it is widely acknowledged that the
Kato-Katz technique lacks sensitivity in areas characterized by low
S. mansoni infection intensities, which is common after treatment
[41]. Second, perhaps CCA might still be detectable in urine 3
weeks after treatment [42,43], while the recommended time for S.
mansoni assessment after treatment is 15–20 days [44]. Third, while
children might have been cured from patent S. mansoni infection,
praziquantel is largely refractory against young developing stages
of the worms [12,13], and hence antigens might still be present in
the urines of young children. Fourth, the POC-CCA cassette
might lack specificity after praziquantel administration. Further
investigations are therefore needed to determine whether or not a
POC-CCA cassette can be utilized for determining praziquantel
efficacy, including the most appropriate time point posttreatment.
Three weeks posttreatment might be too short for assessing
praziquantel efficacy in preschool-aged children, but the longer
one waits, the higher the risk for confounding factors (e.g.,
schistosomula fully developed into adult worms, and reinfection).
In our study, we also thoroughly assessed the safety of crushed
praziquantel given to preschoolers. We observed similar frequen-
cies of adverse events in preschool-aged children as reported by
other groups [26,40], and as observed in school-aged children
[45–47]. Recently, Namwanje and colleagues showed that
praziquantel alone and in combination with mebendazole in the
treatment of S. mansoni and soil-transmitted helminths in
preschool-aged children showed similar safety profiles [48].
However, in the current study, inflammation of the body and
the face was observed in four children (2.5%). Interestingly, these
children were Schistosoma egg-negative at the baseline survey before
drug administration and only one child showed a light positive
POC-CCA result (1+). Inflammation of body and face has been
observed in previous studies [40], raising concern with regard to
the inclusion of preschool-aged children in preventive chemother-
apy campaigns, which has been proposed by different authors
[17,24,25,29]. While preschool-aged children with a confirmed
Table 3. Adverse events 4 and 24 hours after administration
of crushed praziquantel tablets (n= 234).
Adverse event Severity Incidence (%)
4 hours 24 hours
Abdominal pain Light 7 (2.9) 2 (0.9)
Diarrhea 6 (2.6) 3 (1.3)
Nausea 5 (2.1) 0
Vomiting 4 (1.7) 0
Dizziness 3 (1.3) 1 (0.4)
Fatigue 2 (0.9) 2 (0.9)
Fever 2 (0.9) 0
Headache 1 (0.4) 1 (0.4)
Body and face inflammation Moderate 2 (0.9) 2 (0.9)
Total 32 11
The study was carried out in two villages in Azaguie´, south Coˆte d’Ivoire
between June and November 2011, focusing on preschool-aged children.
doi:10.1371/journal.pntd.0001917.t003
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Schistosoma infection must be treated [49], we feel that further
research is still required, including development of an appropriate
pediatric formulation, dose-finding, detailed pharmacokinetic
investigations, and in-depth safety studies, before preventive
chemotherapy be extended from the school-aged population to
preschoolers [18].
In conclusion, our study documents that preschool-aged
children are at risk of schistosomiasis in the Azaguie´ area, south
Coˆte d’Ivoire, with 7% of our per-protocol population patently
infected with S. mansoni and S. haematobium concurrently. Crushed
praziquantel is efficacious against both species in preschool-aged
children. In view of unwanted adverse events in non-infected
children following praziquantel administration, we suggest that
only parasitologically confirmed preschool-aged children should
be given praziquantel. New research is needed to accurately
determine the frequency and severity of adverse events after
praziquantel administration against schistosomiasis in the pre-
school-aged population. There is a need to develop a safe and
user-friendly formulation of praziquantel so that infected children
can be treated at an early stage of infection in order to prevent any
harmful damage in later life.
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